Iron Overload Due to Blood Transfusions

• FDA approval · 2024-12-17
  FDA Approved: DEFERASIROX — Supplemental Application (Dr. Reddy's Laboratories Inc)

  FDA approved Dr. Reddy's Laboratories' supplemental application for deferasirox (generic) under the approved labeling for chronic iron overl…

• FDA approval · 2023-06-23
  FDA Approved: DEFERASIROX — Supplemental Application (Zydus Pharmaceuticals USA Inc.)

  FDA approved a supplemental application for Deferasirox from Zydus Pharmaceuticals USA Inc. under an ANDA, indicating an update to labeling …

• FDA approval · 2020-07-23
  FDA Approved: EXJADE — Supplemental Application (Novartis Pharmaceuticals Corporation)

  The FDA approved a supplemental application for EXJADE (deferasirox) from Novartis Pharmaceuticals Corporation, related to its iron chelatio…

• FDA approval · 2019-11-20
  FDA Approved: DEFERASIROX — Original Application (Dr. Reddy's Laboratories Inc)

  FDA approved Dr. Reddy's Laboratories' original application for deferasirox, a generic iron chelator for chronic iron overload due to blood …

• FDA approval · 2019-11-20
  FDA Approved: DEFERASIROX — Original Application (Ascend Laboratories, LLC)

  FDA approves Ascend Laboratories' original application for the generic iron chelator deferasirox.

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• FDA approval · 2019-07-26
  FDA Approved: JADENU — Supplemental Application (Novartis Pharmaceuticals Corporation)

  FDA approved a supplemental application for Jadenu (deferasirox) from Novartis Pharmaceuticals Corporation.